Who owns Ovid Therapeutics?
- Ticker: OVID
- CUSIP Number: 690469101
Tip: Access positions for across all investors
Analyze quarterly positions in Ovid Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Ovid Therapeutics stock
Who bought or sold Ovid Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| EcoR1 Capital | 6.1M | $19M | 0% | Mar 2024 |
|
| Rubric Capital Management | 5.3M | $16M | -2% | Mar 2024 |
|
| BlackRock | 4.2M | $13M | 19% | Mar 2024 |
|
| BVF | 3.9M | $12M | -44% | Mar 2024 |
|
| Madison Avenue Partners | 3.6M | $12M | 0% | Dec 2023 |
|
| Vanguard Group | 3.0M | $9.1M | 0% | Mar 2024 |
|
| Artal Group | 2.5M | $7.6M | 0% | Mar 2024 |
|
| Acadian Asset Management | 1.7M | $5.0M | -3% | Mar 2024 |
|
| Jpmorgan Chase & Co | 1.6M | $4.8M | -3% | Mar 2024 |
|
| TLS Advisors | 1.3M | $4.0M | 0% | Mar 2024 |
|
| Geode Capital Management | 1.3M | $3.8M | 5% | Mar 2024 |
|
| Prosight Management | 983k | $3.0M | 100% | Mar 2024 |
|
| Blue Owl Capital Holdings | 865k | $2.6M | 0% | Mar 2024 |
|
| Northern Trust | 481k | $1.5M | 0% | Mar 2024 |
|
| Wells Fargo & Company | 434k | $1.3M | -3% | Mar 2024 |
|
| Fft Wealth Management | 414k | $1.3M | 5% | Mar 2024 |
|
| Bridgeway Capital Management | 358k | $1.1M | -22% | Mar 2024 |
|
| Dimensional Fund Advisors | 342k | $1.0M | 41% | Mar 2024 |
|
| UBS O'Connor | 260k | $792k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 230k | $700k | -8% | Mar 2024 |
|
| Charles Schwab Investment Management | 162k | $494k | 0% | Mar 2024 |
|
| Citadel Advisors | 154k | $468k | 1046% | Mar 2024 |
|
| Millennium Management | 146k | $445k | 100% | Mar 2024 |
|
| Empowered Funds | 128k | $391k | 19% | Mar 2024 |
|
| Nuveen Asset Management | 119k | $363k | 4% | Mar 2024 |
|
| Assenagon Asset Management | 114k | $349k | 46% | Mar 2024 |
|
| Morgan Stanley | 100k | $305k | 132% | Mar 2024 |
|
| FMR | 86k | $263k | -6% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 84k | $257k | 4% | Mar 2024 |
|
| Rhumbline Advisers | 83k | $252k | 4% | Mar 2024 |
|
| UBS Group | 73k | $224k | 2% | Mar 2024 |
|
| Tejara Capital | 73k | $223k | 0% | Mar 2024 |
|
| D. E. Shaw & Co | 71k | $217k | -9% | Mar 2024 |
|
| Squarepoint Ops | 68k | $208k | 501% | Mar 2024 |
|
| Jacobs Levy Equity Management | 62k | $190k | 0% | Mar 2024 |
|
| Goldman Sachs Group | 59k | $180k | -5% | Mar 2024 |
|
| Jane Street | 54k | $163k | 5% | Mar 2024 |
|
| Bank of Nova Scotia | 44k | $142k | 0% | Dec 2023 |
|
| Barclays | 42k | $128k | -49% | Mar 2024 |
|
| Two Sigma Investments | 41k | $124k | 100% | Mar 2024 |
|
| SG Americas Securities | 36k | $110k | -10% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 32k | $98k | 75% | Mar 2024 |
|
| MetLife Investment Advisors | 32k | $102k | 0% | Dec 2023 |
|
| American International | 30k | $95k | 0% | Dec 2023 |
|
| First Manhattan | 26k | $79k | 0% | Mar 2024 |
|
| Springbok Capital Management | 26k | $78k | 100% | Mar 2024 |
|
| Tower Research Capital | 24k | $74k | 498% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 24k | $73k | 5% | Mar 2024 |
|
| William Blair $ Company | 24k | $73k | 10% | Mar 2024 |
|
| Ing Investment Management | 23k | $70k | -12% | Mar 2024 |
|
| DCF Advisers | 20k | $60k | -35% | Mar 2024 |
|
| New York State Common Retirement Fund | 19k | $57k | -2% | Mar 2024 |
|
| Bank of America Corporation | 19k | $57k | -66% | Mar 2024 |
|
| T. Rowe Price Associates | 17k | $54k | 22% | Mar 2024 |
|
| ADAR1 Capital Management | 16k | $50k | 24% | Mar 2024 |
|
| ProShare Advisors | 16k | $48k | 100% | Mar 2024 |
|
| Occudo Quantitative Strategies | 14k | $43k | 100% | Mar 2024 |
|
| China Universal Asset Management | 14k | $41k | 66% | Mar 2024 |
|
| Bailard | 13k | $38k | 0% | Mar 2024 |
|
| Citigroup | 12k | $34k | 14% | Mar 2024 |
|
| California State Teachers Retirement System | 6.0k | $18k | -54% | Mar 2024 |
|
| Legal & General Group | 5.2k | $16k | 0% | Mar 2024 |
|
| Summit Investment Advisors | 4.9k | $15k | 0% | Mar 2024 |
|
| Metropolitan Life Insurance Company | 3.3k | $11k | 0% | Dec 2023 |
|
| Royal Bank of Canada | 2.3k | $7.3k | -90% | Mar 2024 |
|
| Amalgamated Bank | 2.0k | $6.0k | -61% | Mar 2024 |
|
| Sandy Spring Bank | 2.0k | $6.1k | 0% | Mar 2024 |
|
| Simplex Trading | 1.2k | $3.0k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 446.00 | $1.4k | 46% | Mar 2024 |
|
| ICA Group Wealth Management | 55.00 | $167.997500 | 0% | Mar 2024 |
|
| Qube Research & Technologies | 54.00 | $165.002400 | 100% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 10.00 | $30.000000 | 100% | Mar 2024 |
|
| Frazier Financial Advisors | 10.00 | $31.000000 | 100% | Mar 2024 |
|
| Sound Income Strategies | 6.00 | $18.000000 | 100% | Mar 2024 |
|
| CWM | 5.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Ovid Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Mirae Asset Global Investments | Dec 2023 | 34k | $110k |
| Virtu Financial | Dec 2023 | 24k | $78k |
| Florida State Board of Administration | Dec 2023 | 17k | $56k |
| Newman Dignan & Sheerar | Dec 2023 | 17k | $53k |
| Jump Financial | Sep 2023 | 16k | $61k |
| Cutler | Dec 2023 | 2.1k | $6.0k |
| Pnc Financial Services | Dec 2023 | 10.00 | $32.000000 |